Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EPS (Basic) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EPS (Basic) over the past 16 years, most recently at -$0.03 for Q2 2025.

  • For Q2 2025, EPS (Basic) rose 80.0% year-over-year to -$0.03; the TTM value through May 2025 reached -$1.28, down 384.44%, while the annual FY2025 figure was -$1.27, 425.64% down from the prior year.
  • EPS (Basic) for Q2 2025 was -$0.03 at Lifecore Biomedical, Inc. \De\, up from -$0.47 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.48 in Q1 2024 and troughed at -$1.32 in Q2 2023.
  • A 5-year average of -$0.27 and a median of -$0.29 in 2021 define the central range for EPS (Basic).
  • On a YoY basis, EPS (Basic) climbed as much as 209.3% in 2023 and fell as far as 1000.0% in 2023.
  • Year by year, EPS (Basic) stood at $0.25 in 2021, then tumbled by 272.0% to -$0.43 in 2022, then skyrocketed by 209.3% to $0.47 in 2023, then tumbled by 153.19% to -$0.25 in 2024, then surged by 88.0% to -$0.03 in 2025.
  • Business Quant data shows EPS (Basic) for LFCR at -$0.03 in Q2 2025, -$0.47 in Q1 2025, and -$0.25 in Q4 2024.